You are here

A dual acting drug for enhancing radiotherapeutic benefit

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43CA180316-01A1
Agency Tracking Number: R43CA180316
Amount: $209,208.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NCI
Solicitation Number: PA13-088
Solicitation Year: 2014
Award Year: 2014
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
PASADENA, CA 91107-3658
United States
DUNS: 788136880
HUBZone Owned: No
Woman Owned: Yes
Socially and Economically Disadvantaged: No
Principal Investigator
 (424) 209-2230
Business Contact
Phone: (424) 209-2230
Research Institution

ABSTRACT: This proposal entitled A dual acting drug for enhancing radiotherapeutic benefit is designed to provide proof of concept evidence that the novel compound EWA001 can protect normal lung tissue from radiation-induced damage within an in vivo model without appreciably protecting neoplastic tissue. The protection of radiation induced lung toxicity from ionizing radiation and in particular, radiation induced pneumonitis and fibrosis, is an unmet need that may benefit thousands of patients considering that more than two thirds will receive radiation therapy during the course of their treatment for cancer with such complications limiting treatment or even resulting in death. In aim 1, we will examine the effect of EWA001 in tumor LLC and human tumor xenografts in vitro and in vivo in conjunction with radiation. In aim 2, we will investigate EWA001's efficacy at protecting against and mitigating radiation induced lung injury in mice. Currently, there is no drug available that would minimize radiation to

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government